Danitracen

Danitracen (NSC 170955) is an orally active, CNS penetrant serotonin antagonist with antidepressant activity. Danitracen reduces serotonin levels in the cerebrum, cerebellum, medulla and the whole brain. Danitracen exhibits anticataleptic effects in rat catalepsy models. Danitracen can be used for catalepsy and depression research[1][2][3].

Product Specifications

CAS Number

[31232-26-5]

Product Name Alternative

NSC 170955; WA 335

UNSPSC

12352005

Target

5-HT Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

OC1C2=C(C=CC=C2)/C(C3=CC=CC=C13)=C4CCN(C)CC/4

Molecular Formula

C20H21NO

Molecular Weight

291.39

References & Citations

[1]Maj J, et al. Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy. Arch Immunol Ther Exp (Warsz) . 1976;24 (2) :197-203.|[2]Kaumeier S, et al. WA 335 (danitracen) : a preliminary evaluation of a potential antidepressant compound. A comparative double-blind study with WA 335 and amitriptyline in the treatment of depressive patients. Curr Ther Res Clin Exp. 1977 Jan;21 (1) :108-13.|[3]Maj J, et al. Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy. Arch Immunol Ther Exp (Warsz) . 1976;24 (2) :197-203.